$2.87 Billion is the total value of EcoR1 Capital, LLC's 71 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 37.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PRTA | PROTHENA CORP PLC | $803,779,000 | +38.6% | 11,284,280 | 0.0% | 27.96% | +29.0% | |
| MORF | MORPHIC HLDG INC | $223,817,000 | -1.3% | 3,951,566 | 0.0% | 7.79% | -8.1% | |
| ANAB | ANAPTYSBIO INC | $203,970,000 | +4.6% | 7,521,024 | 0.0% | 7.10% | -2.6% | |
| RCUS | Buy | ARCUS BIOSCIENCES INC | $178,617,000 | +95.0% | 5,122,359 | +53.6% | 6.21% | +81.5% |
| XNCR | XENCOR INC | $160,233,000 | -5.3% | 4,906,106 | 0.0% | 5.57% | -11.9% | |
| NUVB | NUVATION BIO INC | $136,292,000 | +6.8% | 13,711,517 | 0.0% | 4.74% | -0.6% | |
| ALEC | Buy | ALECTOR INC | $113,985,000 | +29.0% | 4,994,970 | +17.7% | 3.96% | +20.0% |
| MRTX | MIRATI THERAPEUTICS INC | $82,139,000 | +9.5% | 464,298 | 0.0% | 2.86% | +2.0% | |
| GLPG | New | GALAPAGOS NVspon adr | $82,006,000 | – | 1,558,749 | +100.0% | 2.85% | – |
| STTK | Buy | SHATTUCK LABS INC | $75,591,000 | -21.4% | 3,709,072 | +11.8% | 2.63% | -26.8% |
| ORIC | Buy | ORIC PHARMACEUTICALS INC | $72,536,000 | +32.6% | 3,468,944 | +12.2% | 2.52% | +23.4% |
| KURA | KURA ONCOLOGY INC | $69,759,000 | -10.2% | 3,724,437 | 0.0% | 2.43% | -16.4% | |
| RNA | Buy | AVIDITY BIOSCIENCES INC | $67,967,000 | +30.7% | 2,759,505 | +31.2% | 2.36% | +21.7% |
| GRTS | Buy | GRITSTONE BIO INC | $60,056,000 | +92.3% | 5,560,748 | +62.5% | 2.09% | +79.0% |
| RLAY | Sell | RELAY THERAPEUTICS INC | $43,678,000 | -73.4% | 1,385,276 | -69.1% | 1.52% | -75.2% |
| ITOS | Buy | ITEOS THERAPEUTICS INC | $35,185,000 | +32.4% | 1,303,157 | +25.8% | 1.22% | +23.3% |
| NRIX | Sell | NURIX THERAPEUTICS INC | $33,754,000 | -35.3% | 1,126,640 | -42.8% | 1.17% | -39.8% |
| JANX | JANUX THERAPEUTICS INC | $30,541,000 | -13.3% | 1,411,975 | 0.0% | 1.06% | -19.4% | |
| DSGN | Buy | DESIGN THERAPEUTICS INC | $27,369,000 | +9.2% | 1,863,098 | +47.9% | 0.95% | +1.6% |
| BPMC | New | BLUEPRINT MEDICINES CORPcall | $25,933,000 | – | 250,000 | +100.0% | 0.90% | – |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $25,584,000 | – | 1,443,800 | +100.0% | 0.89% | – |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $25,196,000 | – | 1,249,812 | +100.0% | 0.88% | – |
| AKUS | AKOUOS INC | $22,941,000 | -7.5% | 1,975,984 | 0.0% | 0.80% | -13.9% | |
| SLDB | SOLID BIOSCIENCES INC | $21,994,000 | -34.7% | 9,202,702 | 0.0% | 0.76% | -39.2% | |
| EWTX | Buy | EDGEWISE THERAPEUTICS INC | $21,234,000 | -18.7% | 1,279,175 | +4.5% | 0.74% | -24.3% |
| OVID | OVID THERAPEUTICS INC | $20,436,000 | -14.1% | 6,082,200 | 0.0% | 0.71% | -20.0% | |
| New | TANGO THERAPEUTICS INC | $16,809,000 | – | 1,300,000 | +100.0% | 0.58% | – | |
| BLUE | New | BLUEBIRD BIO INC | $15,336,000 | – | 802,507 | +100.0% | 0.53% | – |
| New | ERASCA INC | $14,854,000 | – | 700,000 | +100.0% | 0.52% | – | |
| CNTA | CENTESSA PHARMACEUTICALS PLCsponsored ads | $12,601,000 | -24.8% | 754,545 | 0.0% | 0.44% | -30.0% | |
| SBTX | Sell | SILVERBACK THERAPEUTICS INC | $11,823,000 | -85.4% | 1,184,710 | -54.7% | 0.41% | -86.4% |
| ODT | Buy | ODONATE THERAPEUTICS INC | $10,846,000 | +273.9% | 3,727,261 | +348.4% | 0.38% | +249.1% |
| CRVS | Sell | CORVUS PHARMACEUTICALS INC | $10,072,000 | +5.4% | 2,081,077 | -41.9% | 0.35% | -2.0% |
| IMVT | New | IMMUNOVANT INC | $9,914,000 | – | 1,140,819 | +100.0% | 0.34% | – |
| NUVBWS | NUVATION BIO INC*w exp 07/07/202 | $9,576,000 | +6.8% | 963,333 | 0.0% | 0.33% | -0.6% | |
| CCCC | C4 THERAPEUTICS INC | $8,936,000 | +18.1% | 200,000 | 0.0% | 0.31% | +9.9% | |
| KRON | KRONOS BIO INC | $8,119,000 | -12.5% | 387,357 | 0.0% | 0.28% | -18.7% | |
| NLTX | Sell | NEOLEUKIN THERAPEUTICS INC | $6,222,000 | -71.4% | 860,619 | -63.5% | 0.22% | -73.5% |
| FLAC | Buy | FRAZIER LIFESCIENCES ACQU CO | $5,770,000 | +194.8% | 587,615 | +193.1% | 0.20% | +175.3% |
| ACIU | Sell | AC IMMUNE SA | $5,041,000 | -76.0% | 751,251 | -71.6% | 0.18% | -77.7% |
| NGM | New | NGM BIOPHARMACEUTICALS INCcall | $5,000,000 | – | 245,000 | +100.0% | 0.17% | – |
| CYCN | CYCLERION THERAPEUTICS INC | $4,931,000 | -21.3% | 1,606,276 | 0.0% | 0.17% | -26.5% | |
| JYAC | JIYA ACQUISITION CORP | $4,875,000 | -1.9% | 500,000 | 0.0% | 0.17% | -8.6% | |
| VERV | VERVE THERAPEUTICS INC | $4,700,000 | -22.0% | 100,000 | 0.0% | 0.16% | -27.1% | |
| KNTE | Buy | KINNATE BIOPHARMA INC | $4,029,000 | +592.3% | 175,000 | +600.0% | 0.14% | +536.4% |
| HSAQ | HEALTH SCIENCES ACQ CORP 2 ORD | $3,956,000 | -3.0% | 400,000 | 0.0% | 0.14% | -9.2% | |
| FSII | Buy | FS DEVELOPMENT CORP II | $3,692,000 | +146.6% | 371,014 | +147.3% | 0.13% | +128.6% |
| DYN | DYNE THERAPEUTICS INC | $3,569,000 | -21.1% | 215,000 | 0.0% | 0.12% | -26.6% | |
| IGMS | IGM BIOSCIENCES INC | $2,501,000 | -21.0% | 38,030 | 0.0% | 0.09% | -26.3% | |
| FMTX | Sell | FORMA THERAPEUTICS HLDGS INC | $2,090,000 | -20.5% | 90,141 | -14.7% | 0.07% | -25.5% |
| HLXA | HELIX ACQUISITION CORP | $1,990,000 | -3.9% | 200,000 | 0.0% | 0.07% | -10.4% | |
| BLSA | BCLS ACQUISITION CORP | $1,992,000 | -5.4% | 200,000 | 0.0% | 0.07% | -12.7% | |
| EUCR | EUCRATES BIOMEDICAL ACQU COR | $1,956,000 | -0.7% | 200,000 | 0.0% | 0.07% | -8.1% | |
| FVAM | 5 01 ACQUISITION CORP | $1,964,000 | -1.5% | 200,000 | 0.0% | 0.07% | -9.3% | |
| BOLT | BOLT BIOTHERAPEUTICS INC | $1,848,000 | -20.3% | 150,000 | 0.0% | 0.06% | -26.4% | |
| New | CARIBOU BIOSCIENCES INC | $1,790,000 | – | 75,000 | +100.0% | 0.06% | – | |
| ARYD | ARYA SCIENCES ACQU CORP IVcl a | $1,508,000 | -6.2% | 150,000 | 0.0% | 0.05% | -13.3% | |
| PMVP | PMV PHARMACEUTICALS INC | $1,490,000 | -12.8% | 50,000 | 0.0% | 0.05% | -18.8% | |
| BCAB | BIOATLA INC | $1,472,000 | -30.5% | 50,000 | 0.0% | 0.05% | -35.4% | |
| RPTX | REPARE THERAPEUTICS INC | $1,286,000 | -17.5% | 50,000 | 0.0% | 0.04% | -22.4% | |
| MGTX | MEIRAGTX HLDGS PLC | $1,250,000 | -15.0% | 94,819 | 0.0% | 0.04% | -21.8% | |
| VYGR | New | VOYAGER THERAPEUTICS INC | $1,173,000 | – | 445,992 | +100.0% | 0.04% | – |
| TMPM | TURMERIC ACQUISITION CORPcl a | $979,000 | -1.0% | 100,000 | 0.0% | 0.03% | -8.1% | |
| CMAXW | CAREMAX INC*w exp 06/08/202 | $986,000 | -23.6% | 100,000 | 0.0% | 0.03% | -29.2% | |
| EUCRW | EUCRATES BIOMEDICAL ACQU COR*w exp 10/23/202 | $652,000 | -0.6% | 66,666 | 0.0% | 0.02% | -8.0% | |
| FLACW | FRAZIER LIFESCIENCES ACQU CO*w exp 11/30/202 | $655,000 | +0.6% | 66,665 | 0.0% | 0.02% | -4.2% | |
| OMEG | OMEGA ALPHA SPACcl a | $487,000 | -2.2% | 50,000 | 0.0% | 0.02% | -10.5% | |
| New | SURROZEN INC*w exp 10/28/2025 | $471,000 | – | 66,665 | +100.0% | 0.02% | – | |
| TMPMW | TURMERIC ACQUISITION CORP*w exp 10/08/202 | $326,000 | -1.2% | 33,333 | 0.0% | 0.01% | -8.3% | |
| SRRK | New | SCHOLAR ROCK HLDG CORP | $271,000 | – | 8,208 | +100.0% | 0.01% | – |
| ALPN | Sell | ALPINE IMMUNE SCIENCES INC | $75,000 | -98.4% | 7,001 | -98.7% | 0.00% | -98.3% |
| FSTX | Exit | F-STAR THERAPEUTICS INC | $0 | – | -46,000 | -100.0% | -0.02% | – |
| CHFWWS | Exit | CONSONANCE HFW ACQUISITION C*w exp 10/28/202 | $0 | – | -66,665 | -100.0% | -0.02% | – |
| CHFW | Exit | CONSONANCE HFW ACQUISITION C | $0 | – | -200,000 | -100.0% | -0.07% | – |
| NGM | Exit | NGM BIOPHARMACEUTICALS INC | $0 | – | -143,567 | -100.0% | -0.11% | – |
| MGTA | Exit | MAGENTA THERAPEUTICS INC | $0 | – | -366,867 | -100.0% | -0.13% | – |
| SYRS | Exit | SYROS PHARMACEUTICALS INC | $0 | – | -1,000,000 | -100.0% | -0.20% | – |
| ALVR | Exit | ALLOVIR INC | $0 | – | -447,012 | -100.0% | -0.33% | – |
| BCTG | Exit | BCTG ACQUISITION CORP | $0 | – | -800,000 | -100.0% | -0.34% | – |
| ZNTL | Exit | ZENTALIS PHARMACEUTICALS INC | $0 | – | -200,000 | -100.0% | -0.40% | – |
| KDNY | Exit | CHINOOK THERAPEUTICS INC | $0 | – | -931,650 | -100.0% | -0.49% | – |
| BCEL | Exit | ATRECA INC | $0 | – | -2,426,685 | -100.0% | -0.77% | – |
| ARVN | Exit | ARVINAS INC | $0 | – | -321,724 | -100.0% | -0.93% | – |
| KYMR | Exit | KYMERA THERAPEUTICS INC | $0 | – | -519,416 | -100.0% | -0.94% | – |
| TBIO | Exit | TRANSLATE BIO INC | $0 | – | -1,048,976 | -100.0% | -1.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2021-11-22
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
| XENCOR ORD | 25 | Q3 2023 | 12.6% |
| ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
| FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
| PROTHENA ORD | 20 | Q3 2023 | 28.0% |
| IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
| GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
| MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
| ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
| TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
| 2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
| Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
| Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
| Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-08 |
| 3 | 2024-03-26 |
| SC 13G/A | 2024-03-26 |
| SC 13G | 2024-03-11 |
| SC 13D | 2024-02-22 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.